April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Effects of Topical Human Amniotic Fluid and Human Serum in a Mouse Model of Keratoconjunctivitis Sicca
Author Affiliations & Notes
  • G. G. Quinto
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • W. Camacho
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • J. Castro-Combs
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • L. Li
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • R. T. Kashiwabuchi
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • S. A. R. Martins
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • P. Wittmann
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • M. Campos
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • A. Behrens
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  G.G. Quinto, None; W. Camacho, None; J. Castro-Combs, None; L. Li, None; R.T. Kashiwabuchi, None; S.A.R. Martins, None; P. Wittmann, None; M. Campos, None; A. Behrens, Inventor/Patent, P.
  • Footnotes
    Support  Research to Prevent Blindness, NY
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3660. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. G. Quinto, W. Camacho, J. Castro-Combs, L. Li, R. T. Kashiwabuchi, S. A. R. Martins, P. Wittmann, M. Campos, A. Behrens; Effects of Topical Human Amniotic Fluid and Human Serum in a Mouse Model of Keratoconjunctivitis Sicca. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3660.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effects of topical human amniotic fluid (HAF), topical human serum (HS), and topical artificial tears for the treatment of ocular surface disease in a dry eye model.

Methods: : Thirty C57BL/6 mice were divided into 3 treatment groups: HAF, HS or preservative-free artificial tears. Under direct visualization with an operating microscope, mice received a transconjunctival injection of 0.05mL of botulinum toxin B (BTX-B) solution into the left lacrimal gland. Tear production and ocular surface fluorescein staining were evaluated in each mouse in 6 time points during a 4-week experiment period. Goblet cell density was assessed in stained histological sections. Apoptotic keratocytes were evaluated by TUNNEL-test assay.

Results: : No differences among groups were found at baseline. Significant decrease in tear production was observed 3 days after BTX-B injection in all groups. At week 1, HAF and HS groups were able to improve tear production compared to control group (P <0.001 and P=0.003, respectively). The control group never reached its tear production baseline values in 4 weeks of therapy. The fluorescein staining started appearing noticeably at day 3. At week 2, HAF improved significantly the staining score compared to HS (P=0.043) and control (P=0.007) groups. HS group demonstrated statistically significant difference when compared to control group only at week 4 (P=0.047). Goblet cell density was significantly decreased in the control group compared to HAF and HS groups (P<0.001), but no statistical difference was obtained between the latter groups. We did not observe any difference in the amount of TUNEL positive keratocytes among the different groups.

Conclusions: : HAF was superior to HS and artificial tears to improve corneal staining within 2 weeks of therapy in this induced mouse model of KCS. Further studies need to be performed to validate the efficacy of these promising medications and to ascertain whether the findings of this study can translate into a clinical benefit to patients with ocular surface epithelial disorders associated with dry eye.

Keywords: cornea: tears/tear film/dry eye • cornea: clinical science • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×